腾博会官网·[中国]-诚信为本,专业服务!

Recently, the "2022 Top 100 China Biopharmaceutical Enterprises List" which includes series of lists launched by Times Data of Times Media Group has been launched one after another, and on October 10, the " Top 20 Biopharmaceutical Enterprises with Biggest Innovation Potential in 2022 List" was released, and Sino Biopharm was ranked fourth.

On September 26, Sino Biopharm announced that TDI01, a Class I innovative drug developed by the Group's subsidiary, Beijing Tide Pharmaceutical Co., Ltd., was approved by the State Drug Administration of China on September 23, 2022 to conduct clinical trials for COVID-19. TDI01 was previously approved for clinical trials in China and the U.S. for idiopathic pulmonary fibrosis and in China for pneumoconiosis.

On September 22, Sino Biopharm announced that on September 21, 2022, a subsidiary of the Group, ChiaTai Tianqing Pharmaceutical Group Company Limited (CTTQ), entered into a formal license agreement with Inventiva S. A. (Inventiva) to develop, manufacture and commercialize lanifibranor in mainland China, Hong Kong, Macau and Taiwan (Greater China region). Lanifibranor, Inventiva's core product for the treatment of non-alcoholic steatohepatitis (NASH) and other underlying metabolic diseases.

On September 2, the first phase of the construction of Anhui Linquan Medical Hope School, which was supported by CTTQ, Chiatai Tianqing, was completed. Zhai Qi, deputy governor of Linquan County; Shui Dong, deputy director of Linquan Education Bureau; Zhang Dahong, principal of Chengdong Street Central School; Zhang Kui, principal of Linquan Medical Hope School and Zhuang Xinglong, vice president of CTTQ attended the completion ceremony.

On the morning of August 27, Li Qiang, Secretary of Shanghai Municipal Party Committee, met with the representatives of the 3rd Shanghai Innovation and Entrepreneurship Youth 50 Forum. Mr. Tse, Eric S Y, CEO of Sino Biopharm, attended the meeting as a representative of the Youth 50 Forum.

On August 26, the 13th "Top Ten Outstanding Youths of Lianyungang" jointly organized by the Organization Department, Propaganda Department and United Front Work Department of Lianyungang Municipal Committee, Communist Youth League, Municipal Newspaper and Media Group, Municipal Radio and Television Media Group, and Municipal Youth Federation was selected.

On the morning of August 24, Sino Biopharm (HK.01177) held its 2022 interim results conference and the first Investor Day in Beijing. The company's Chairwoman of the Board of Directors, Miss Tse, Theresa Y Y, the new Chief Executive Officer (CEO), Mr. Tse, Eric S Y, and the company's senior management attended the event, which was also participated by investors and media from around the world through offline and online means.

On the evening of August 14, Shaanxi Provincial Party Secretary Liu Guozhong met with President of CP Pharmaceutical Group and the General Association of Shaanxi Entrepreneurs Cheng Cheung Ling and her entourage, and had a discussion with the representatives attending the 12th Global Qin Business Conference.

Recently, China National Intellectual Property Administration announced the decision of the 23rd China Patent Award, and the compound patent of Anlotinib, a new class 1 drug in the field of anti-tumor of Sino Biopharm CTTQ, "Spiro-substituted compounds as angiogenesis inhibitors"(Patent No. ZL200880007358.X), won the "China Patent Gold Award"

Recently, Nanjing Intellectual Property Office issued the "Decision on the Recognition of 2022 Nanjing Excellent Patent Award (Ning Zhi [2022] No. 25)", in which Nanjing Chia Tai Tianqing, a subsidiary of Sino Biopharm, won the Nanjing Excellent Patent Award for its invention patent "a method of preparing idarubicin hydrochloride".